Cancer clinical trials in the region Occitanie

306 currently recruiting clinical trials
Region Occitanie

Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy
AstraZeneca
Early Access Lymphoma
B cell lymphoma Large B cell lymphoma 2 3 or more
Systemic Treatment-Naive
Hoffmann-La Roche
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR 1 Targeted therapy
Systemic Treatment-Naive
Janssen
Early Access Lymphoma
B cell lymphoma Large B cell lymphoma 1
Systemic Treatment-Naive
Hoffmann-La Roche
Phase 3 Lung cancer #NCT06119581 #2023-503412-33-00
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic KRAS G12C None Systemic Treatment-Naive
BRAF EGFR HER2 MET NTRK-1/2/3 RET ROS-1 Immunotherapy Chemotherapy Targeted therapy
Hôpital Larrey (Toulouse )
Eli Lilly et compagnie
Phase 3 Breast cancer #NCT06382948
HER2 Negative HR Positive Locally Advanced Metastatic ESR 1 2 Targeted therapy Hormone therapy
ESR Systemic Treatment-Naive Chemotherapy
IUCT Oncopôle (Toulouse)
MedSIR
Phase 3 Lung cancer #NCT06881784 #2024-518154-16-00
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic Other KRAS HRAS KRAS G12C KRAS non G12C KRAS G12D NRAS 1 2 Immunotherapy Chemotherapy
Systemic Treatment-Naive
Hôpital Larrey (Toulouse ), Institut du cancer de Montpellier (Montpellier)
Revolution Medicines, Inc.
Phase 3 Stomach and esophageal cancer #NCT06901531 #2024-519773-19-00
Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic Claudin 18.2 None Systemic Treatment-Naive CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
HER2 Immunotherapy Chemotherapy
Centre Hospitalier de Carcassonne (Carcassonne), Institut du cancer de Montpellier (Montpellier)
Astellas Pharma Développement mondial, Inc.